At a glance
ClinicalIndex Comparison RecordN/ACompleted· 41 enrolled
Drug / intervention
Calcitriol +1 moredrug
Likely dose
Calcitriol 0.75 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Hormonal Mechanisms for Vitamin D Receptor Agonist Therapy in Diabetes: The VALIDATE-D Study
In Brief
A clinical study evaluating Calcitriol and Placebo for Type 2 Diabetes and Obesity. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate whether vitamin D receptor agonist therapy lowers renin-angiotensin system activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Obesity
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartSep 2012
Primary CompletionDec 2015
TodayJul 2026
First PostedJul 6, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.0 years ago
Interventions
Calcitrioldrug
Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
Placebodrug
Subjects will receive placebo for 3 weeks.